TPG Capital has signed a binding agreement to acquire a majority stake in DOC Generici from ICG and Mérieux Equity Partners. The strategic rationale for the transaction is driven by the continued expansion of the Italian generic drug market and DOC Generici's position as a reference brand for patients and healthcare providers. TPG intends to partner with the existing management team to accelerate the company’s leadership through significant investment in organic growth and external consolidation. This acquisition represents a continuation of the company's successful history as a private equity-backed consolidation platform, following previous ownership cycles under Charterhouse, CVC, and ICG. The entry of TPG is expected to provide the capital and global infrastructure necessary to further diversify the product portfolio and optimize the supply chain, ensuring the long-term delivery of high-quality, low-cost medication within the European regulatory framework.

ICG acquired 100% of DOC Generici from CVC Capital Partners, marking the company's third private equity cycle. Merieux Equity Partners joined as a strategic co-investor to leverage its industrial expertise in life sciences. The deal was financed by a syndicate of banks including UniCredit, BNP Paribas, Credit Agricole, and Barclays. The investment thesis was built on DOC's resilient "asset-light" business model, which delivers high margins and strong cash flow conversion. Under ICG's ownership, the group aims to further expand its product pipeline and potentially explore international M&A to diversify its purely Italian revenue base.

CVC Capital Partners acquired 100% of DOC Generici from Charterhouse Capital Partners, outbidding other major PE firms like Blackstone in a competitive auction. The transaction was supported by a debt package provided by UniCredit and HSBC. The deal represented a highly successful exit for Charterhouse, which reportedly achieved an Internal Rate of Return (IRR) of 40% and a 2.7x money multiple on its 2013 investment. CVC's strategy for the investment was to leverage DOC's dominant market share and asset-light structure to drive organic growth as generic penetration in Italy continued to increase towards European averages.